NASDAQ: KLRSKalaris Therapeutics Inc Stock
$2.39-0.03 (-1.24%)
Updated Jul 18, 2025
KLRS Price
$2.39
Fair Value Price
$0.17
Market Cap
$44.70M
52 Week Low
$2.28
52 Week High
$24.15
P/E
-0.29x
P/B
0.7x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.61
Operating Cash Flow
-$31M
Beta
1.46
Next Earnings
Aug 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
KLRS Overview
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KLRS's potential to beat the market
- KLRS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KLRS
RankedUnranked of 476
RankedUnranked of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.40 | A | |
| $8.63 | A | |
| $67.86 | A |
Be the first to know about important KLRS news, forecast changes, insider trades & much more!
KLRS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KLRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KLRS ($2.39) is overvalued by 1,310.5% relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KLRS ($2.39) is not significantly undervalued (1,310.5%) relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KLRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KLRS due diligence checks available for Premium users.
Valuation
KLRS fair value
Fair Value of KLRS stock based on Discounted Cash Flow (DCF)
Price
$2.39
Fair Value
$0.17
Overvalued by
1,310.50%
KLRS ($2.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KLRS ($2.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KLRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KLRS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.29x
Industry
-179.53x
Market
31.42x
KLRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.7x
Industry
4.56x
KLRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KLRS's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.2M
Profit Margin
0%
KLRS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$103.1M
Liabilities
$39.2M
Debt to equity
0.61
KLRS's short-term assets ($102.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KLRS's short-term assets ($102.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KLRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KLRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
$0.0
Financing
$107.3M
KLRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KLRS vs Biotech Stocks
Kalaris Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.